Kornimate/medical-research-clean huggingface dataset:
performance of red tinted contact lenses on colour defects

Conditions: Color Vision Defects; Color Blindness

Summary: this study aimed to relate and compare the performance of 4 types of red-tinted contact lenses (cl) with the total error score (tes) from the farnsworth-munsell 100 hue test on colour deficient subjects. only 6 subject with colour vision defect was tested in this study.

six congenital cvd subjects were recruited. after colour vision screening using ishihara plate, the farnsworth-munsell 100 hue test was carried out to determine the type and severity of colour vision deficiency. four types of red-tinted cl (type a, b, c and d) were used. the performance of each of these lenses was determined through the comparison of error scores in the ishihara test before and after wearing tinted contact lens on only the non-dominant eye. then, the transmittance of each tinted cl was determined using a spectrophotometer. all these lenses were fitted on the subjects in one day where the subjects were given a 30-minute break for each intervention.

Eligibility criteria:
inclusion criteria: * age range 18-40 years * all sex * color defect diagnosed with ishihara test * no contraindication in contact lens wear exclusion criteria: * have ocular and systemic diseases

Keywords: anomalous trichromats color vision defect contact lenses
descemet membrane endothelial keratoplasty combined with intraocular lens exchange: sequential versus combined surgery

Conditions: Pseudophakic Bullous Keratopathy; Anterior Chamber Intraocular Lens

Summary: surgical treatment of corneal endothelial decompensation in the presence of an anterior chamber intraocular lens (ac iol) is technically challenging. the ultimate management is to perform descemet membrane endothelial keratoplasty (dmek). however , unfolding the dmek graft in the presence of an ac iol can be difficult and injurious to the graft so the investigators recommend exchanging the ac iol with a posterior chamber iol first. in this study , the investigators aim to compare the outcome and complications of performing dmek and iol exchange as combined one stage surgery versus .sequential 2 stage procedure

pseudophakic bullous keratopathy is the second leading indication for endothelial keratoplasty. one of the main controversies in the management of pbk in the presence of an ac iol is whether to retain the iol or perform an iol exchange with a pc iol. the investigators believe that retention of an ac iol can be hazardous to the dmek graft due to reduced depth of the anterior chamber and traumatic touch between the graft and the iol during graft unfolding and even postoperatively. on the other hand , performing an iol exchange is relatively time consuming and requires excess manipulation of the iris tissue with the risk of intraoperative hyphema and postoperative inflammation which can affect the endothelial graft survival and cell count. aim of the study : to compare the outcome and complications between performing intraocular lens (iol) exchange and descemet membrane endothelial keratoplasty (dmek) as single stage versus two stage procedure in the management of pseudophakic bullous keratopathy associated with anterior chamber iol. methods : the study will be a prospective randomized controlled trial. eligible subjects with pseudophakic bullous keratopathy and ac iol will be assigned into two groups each comprising 10 eyes. one group will undergo ac iol exchange with posterior chamber (pc) iol ( poly methyl methacrylate (pmma) lens or iris claw lens if there is no adequate capsular support) combined with dmek in the same setting. the other group will undergo 2 stage procedure ; first one is iol exchange , iridoplasty (if required) and inferior peripheral iridectomy and the second stage is dmek one month later.

Eligibility criteria:
inclusion criteria: 1. patients having pseudophakic bullous keratopathy associated with an anterior chamber intraocular lens. 2. age above 18 years old. exclusion criteria: 1. patients with corneal stromal scarring . 2. patients who had prior glaucoma drainage devices implantation. 3 patient with non-repairable loss in the iris tissue.

Keywords: descemet membrane endothelial keratoplasty dmek anterior chamber intraocular lens ac iol pseudophakic bullous keratopathy pbk
reverse total shoulder arthroplasty in patients who exceeded their life-expectancy: a retrospective study

Conditions: Reverse Total Shoulder Arthroplasty

Summary: reverse total shoulder arthroplasty (rtsa) has become an established treatment for cuff arthropathy, severe osteoarthritis and in certain fracture cases. due to the increasingly aging population, patients who have already exceeded their life-expectancy pose a significant challenge to the shoulder surgeon. therefore, we wanted to investigate patient demographics, hospital stay length, complication rate functional outcome, patient reported outcome scores and mortality retrospectively for patients, who were older than 83 years at time of implantation of a rtsa.

this is a retrospective single institution study. all patients older than 83 years who received a reverse shoulder arthroplasty from 2008 until 2019 are included. elective cases are compared to fracture cases (patient demographics, length of hospital stay, complication rate, functional outcome, patient reported outcome scores and mortality).

Eligibility criteria:
inclusion criteria: * patients older than 83 years at time of surgery * patients who received a reverse total shoulder arthroplasty exclusion criteria: * patients younger than 83 years at time of surgery

Keywords: reverse total shoulder arthroplasty rtsa elderly proximal humerus fracture cuff arthropathy outcome complications
effect of acupuncture on the microbiota-gut-brain axis in crohn's disease

Conditions: Crohn Disease

Summary: multidisciplinary techniques such as multimodal neuroimaging, microbiology, and bioinformatics were applied to study the differences in correlation characteristics between gut microbes, functional brain networks, and peripheral inflammation among patients with active crohn's disease (cd), cd in remission, and healthy subjects.


Eligibility criteria:
inclusion criteria: 1. 18 ≤ age ≤ 75 years, gender is not limited; 2. disease in mildly or moderately active stage: 150 ≤ cdai \< 450 and at least one of the following is met: serum c-reactive protein ≥ 5 mg/l, faecal calreticulin ≥ 250 μg/g, or endoscopic ulceration, or remission stage: cdai \< 150 and at least one of the following is met: serum c-reactive protein \< 5 mg/l, faecal calreticulin \< 250 μg/g, or endoscopic no ulcers; 3. not taking or taking the following medications: mesalazine (≤4 g/d and have been taking for ≥1 month), prednisone (≤15 mg/d and have been taking for ≥1 month), and/or azathioprine (≤1 mg/kg/d and have been taking for ≥3 months); 4. those who have not used biologics within 3 months prior to study entry; 5. those who have never received acupuncture treatment; 6. understand, agree to participate in the study and sign an informed consent form. exclusion criteria: 1. patients who have recently prepared for pregnancy or are pregnant or breastfeeding; 2. patients with severe organic pathology; 3. patients with confirmed psychosis; 4. patients who are suffering from multiple diseases at the same time and taking other drugs for a long time which may affect the observation of this clinical trial; 5. patients with severe extra-intestinal manifestations such as severe skin diseases (e.g., erythema nodosum, gangrenous pyoderma, etc.), ocular lesions (e.g., iritis, uveitis, etc.), and thromboembolic diseases; 6. those with severe intestinal fistulae, abdominal abscesses, intestinal stenosis and intestinal obstruction, perianal lesions (perianal abscesses, etc.), gastrointestinal haemorrhage, intestinal perforation and other complications; 7. those suffering from short bowel syndrome, those who have undergone abdominal or gastrointestinal surgery within the last six months; 8. those who are unable to perform acupuncture due to the presence of skin diseases or defects in the area selected for acupuncture.

Keywords: acupuncture brain-gut interaction
use of laser assisted new attachment procedure and low level laser therapy for periodontitis patients

Conditions: Periodontitis

Summary: in this study, it is evaluated the effects of laser assisted new attachment procedure (lanap) and low level laser therapy (lllt) and on clinical, biochemical and radiographic parameters in addition to non-surgical periodontal treatment (nspt).

the study was designed as a randomized-controlled, single-blind and parallel design consisting of 80 patients with chronic periodontitis. study consists of 4 groups, with 20 patients in each group. group 1 received only nspt, group 2 received nspt+lanap, group 3 received nspt+lllt, and group 4 received nspt+lanap+lllt. clinical measurements of patients and gingival crevicular fluid (gcf) were taken before treatment and after 1 and 3 months. in gcf, interleukin-1beta, interleukin-10 and vascular endothelial growth factor were analyzed. standard periapical radiographs were taken for radiographic measurements. in moderate (4-6 mm) and deep pockets (7 mm and above), it was found that all groups treated with laser significantly decrease pocket depth (pd) and clinic attachment level (cal) compared to group 1. group 3 caused significantly less gingival recession than all other groups. there was no statistical difference between the groups in biochemical markers. radiographic analysis revealed that only group 2 achieved significant bone filling compared to group 1. bot lanap and lllt application in the deep pockets provide an additional contribution to nspt. it has been found that lllt administration leads to decrease in pd by creating a minimum recession.

Eligibility criteria:
inclusion criteria: * periodontitis of periodontal stage ii, iii, or iv with grades b * with at least 12 teeth in the mouth and had ≥4 teeth but not all of them in the same quadrant * with probing depth of ≥5 mm, clinical attachment level of ≥4 mm * radiographic evidence of alveolar bone loss exclusion criteria: * smoking * pregnancy and lactation * using antibiotics in the last 6 months and anti-inflammatory drugs in the last 3rd months, * having the systemic disease and the use of the drug that will affect the periodontal condition, having restoration of the adjacent tooth to be collected gingival crevicular fluid

Keywords: laser assisted new attachment procedure low level laser therapy periodontitis non-surgical periodontal therapy
brain development in young children following mild traumatic brain injury - pilot study

Conditions: TBI (Traumatic Brain Injury)

Summary: concussions (also known as mild traumatic brain injury) are common in young children. in some children, they can lead to short- and long-term difficulties. however, our knowledge of the exact consequences of injuries on young children's brains and behavior is limited. these consequences may be different in children under 6, as their brains are fragile and undergoing significant developmental changes. the aim of this study is to determine the extent to which a concussion sustained before the age of 6 years is associated with changes in young children's brain structure, function and behaviours, using a brain imaging. in this study, the results of a group of 30 children with a concussion will be compared to those of 30 children of the same age with an orthopaedic injury to the upper or lower limbs.


Eligibility criteria:
inclusion criteria: * patient group with mild traumatic brain injury (mtbi) : 1. children aged between 36 months (3 years) and 71 months and 31 days (5 years; before their 6th birthday) 2. presentation to the emergency department within 48 hours post-injury 3. documented, unintentional traumatic event (e.g. blow, fall, etc.) resulting in non-penetrating head injury 4. diagnosis of mtbi (world health organization (who) paediatric diagnostic criteria) * control group with orthopaedic injury: 1. children aged between 36 months (3 years) and 71 months and 31 days (5 years; before their 6th birthday) 2. presentation to the emergency department within 48 hours post-injury 3. documented, unintentional traumatic event (e.g. blow, fall, etc.) resulting in trauma to an upper or lower limb 4. diagnosis of simple fracture, sprain, contusion or unspecified trauma to a limb (mild). exclusion criteria: * diagnosis of previous tbi (any severity, any age) * intentional injury, * administration of sedative drugs that can alter brain function * complications following injury * mri contraindication, * parent non-fluent in french, * prematurity, * diagnosis of a severe neurological, developmental, or psychiatric disorder * children in foster care at the time of recruitment
open-label, pharmacokinetic, safety and efficacy study of adjunctive brivaracetam in children with epilepsy.

Conditions: Epilepsy

Summary: initial study in children with epilepsy to evaluate the pharmacokinetics, safety, tolerability and preliminary efficacy of adjunctive treatment with brivaracetam, and to develop dosing adaptations for future studies.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of epilepsy * subject having at least 1 seizure (any type) during the 3 weeks before first visit * stable dosing of 1-3 concomitant antiepileptic drugs exclusion criteria: * pregnant or nursing females * concomitant use of levetiracetam * epilepsy secondary to a progressive cerebral disease/tumor or other neurodegenerative disease * history of status epilepticus * clinically significant acute or chronic illness, underlying disease or medication condition * history of suicide attempt

Keywords: brivaracetam epilepsy child pharmacokinetics adolescents
a study comparing the pharmacodynamic properties of insulin viaject™, regular human insulin, and insulin lispro

Conditions: Diabetes Mellitus

Summary: evaluation of post-prandial blood glucose excursions after a standardized meal and pre meal injections of individual doses of the study insulins.


Eligibility criteria:
inclusion criteria: 1. established diagnosis of type 1 diabetes for not less than 5 years 2. hba1c values of not more than 9% 3. age: 19 to 70 years 4. sex: male or female 5. body mass index: 18 - 28 kg/m2 6. informed consent must be obtained in writing for all volunteers. exclusion criteria: 1. type 2 diabetes mellitus. 2. history of hypersensitivity to any of the components in the study medication. 3. history of severe or multiple allergies. 4. treatment with any other investigational drug in the last 1 month before study entry. 5. treatment with any concomitant medication that in the judgment of the investigator. would interfere with the study results. 6. progressive disease likely to prove fatal (e.g. malignancies). 7. current drug or alcohol abuse, or a history which in the opinion of the investigator will impair subject safety or protocol compliance. 8. having a significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and/or hematological disease as evaluated by the investigator. 9. blood donation within the last 30 days. 10. a women who is lactating. 11. pregnant women or women intending to become pregnant during the study. 12. a sexually active woman of childbearing age not actively practicing birth control by using a medically accepted device or therapy. 13. positive serology for hiv, hepatitis b or hepatitis c. 14. abnormal ecg, safety lab or physical examination results that are deemed clinically significant by the investigator. 15. a lack of compliance or other reasons which, in the opinion of the investigator, prevent the participation of the subject in the study.

Keywords: mealtime insulin rapid acting insulin ultra fast viaject prandial insulin
educational program to increase colorectal cancer screening: a cluster trial

Conditions: Colorectal Cancer

Summary: * hypothesis 1. when compared to passive dissemination, active dissemination will result in greater participant enrollment. * hypothesis 2. the intervention will be offered with equal fidelity in churches, clinics and community sites. * hypothesis 3. knowledge of crc screening and perceived risk of crc will be positively correlated.

in this study, investigators aim to evaluate 20 community coalitions and 7,200 participants by: testing passive and active approaches to disseminating the educational program to increase colorectal cancer screening (epics) to increase screening rates for colorectal cancer; measuring the extent to which epics is accepted and the fidelity of implementation in various settings and estimating the potential translatability and public health impact of epics. this four-arm cluster randomized trial (five community coalitions plus 1,800 african americans, 50-74 years of age, who are not current on colorectal cancer (crc) screening per arm) compares the following implementation strategies: (1) web access to facilitator training materials and toolkits without technical assistance (ta); (2) web access, but with technical assistance (ta); (3) in-person access to facilitator training materials and toolkits without ta and (4) in-person access with ta. primary outcome measures are the reach (the proportion of representative eligible community coalitions and individuals participating in the trial) and effectiveness (post-intervention changes in crc screening rates). secondary outcomes include adoption (percentage of community coalitions implementing the epics sessions) and implementation (quality and consistency of the intervention delivery). the extent to which community coalitions continue to implement epics post-implementation (maintenance) will also be measured. cost-effectiveness analysis will be conducted to compare passive to active dissemination costs. investigators believe that implementing this evidence-based colorectal cancer screening intervention in partnership with community coalitions will result in more rapid adoption than traditional top-down approaches, and that changes in community crc screening practices are more likely to be sustainable over time. with its national reach, this study has the potential to enhance understanding of barriers and enablers to the uptake of educational programs aimed at eliminating cancer health disparities.

Eligibility criteria:
inclusion criteria: * african americans, 50-74 years of age, who are not current on crc screening, are eligible for study participation exclusion criteria: * individuals with a personal history of crc or inflammatory bowel disease, blindness or severe hearing impairment; dementia; or other condition with life expectancy less than two years, are ineligible for participation

Keywords: community-based participatory research colorectal cancer screening
screening of subclinical hypothyroidism in pregnant women

Conditions: Subclinical Hypothyroidism

Summary: this study may help the physicians to evaluate the practice of universal screening of sub-clinical hypothyroidism and thyroid-stimulating hormone level. detection of sub-clinical hypothyroidism early in pregnancy through thyroid-stimulating hormone sampling in the first trimester will allow achieving proper management and better maternal and neonatal outcome of these patients.

this is a cross-sectional study will be carried out on women attending obstetrics outpatient clinic in sohag university hospitals between april and 1st december 2023 for the booking antenatal care visit and to be invited to enroll in the study. the attending physician will explain the nature of the study to the cases, the blood samples will be collected and to be assessed for the routine antenatal screening complete blood count, random blood sugar, hepatitis b virus and hiv, the same blood sample will be used to asses tsh level.

Eligibility criteria:
inclusion criteria: * age group 18 years to 45 years. * first trimester pregnant women. exclusion criteria: * women with known thyroid disorders or previous thyroidectomy. * pregnant women with hyperemesis gravidarum. * molar pregnancy.
prescription and utilization of low molecular weight heparin in usual medical practice for the curative treatment of venous thromboembolism in patients with cancer

Conditions: Venous Thromboembolism

Summary: the study purpose is to document the prescription and the use of low molecular weight heparin in usual medical practice in patients with cancer and established venous thromboembolism. this study also aims at gathering epidemiological data on the low molecular weight heparin therapy of venous thromboembolism in patients with cancer.


Eligibility criteria:
inclusion criteria: * subjects must provide informed consent * men or women aged 18 years or more * ongoing cancer disease recent diagnosis of veinous thromboembolism treatment with low molecular weight heparin before entry into the study exclusion criteria: - contraindication to the use of low molecular weight heparin

Keywords: venous thromboembolism cancer low molecular weight heparin
transdermal lisuride: a trial for the treatment of patients with restless legs syndrome (rls)

Conditions: Restless Legs Syndrome

Summary: the objective of this trial is to compare an individually optimized dose of the lisuride tts patch against placebo and against an individually optimized dose of oral ropinirole (active- and placebo-controlled design) in idiopathic and uremic rls patients with regard to efficacy, safety, and quality of life.

approximately 300 patients will be randomized to receive either lisuride, ropinirole or placebo in a 2:1:1 fashion. after completion of 12 weeks of double-blind treatment, eligible patients will have the option to continue treatment with the lisuride patch for further 36 weeks in an open-label extension of the study. primary outcome: changes in the total score of the international restless legs severity scale (irls) from baseline to end of double-blind treatment (12 weeks) will be used as primary efficacy outcome measure. secondary objectives are to evaluate quality of life, safety and tolerability. after the double-blind period, long-term efficacy of lisuride will be assessed for further 36 weeks in an open-label extension of the study.

Eligibility criteria:
inclusion criteria: * idiopathic or uremic rls * rls diagnostic index (rls-di) \> 10 * total score in the irls rating scale ≥ 15 at baseline * no previous treatment for rls or insufficient current therapy exclusion criteria: * secondary rls, e.g. due to iron deficiency (exception: uremia) * history or presence of sleep disorders other than rls

Keywords: restless legs syndrome dopamine agonist lisuride ropinirole
safety/efficacy of systane free vs refresh tears

Conditions: Dry Eye

Summary: the objective of this study is to evaluate the safety and efficacy of systane free fid 105783 in comparison to refresh tears lubricant eye drops (allergan) in a specified population of dry eye patients.


Eligibility criteria:
inclusion criteria: * \> = 3 stain using nei grid and need artificial tears at least some of the time.